For another instance, Metformin, an old drug widely used to treat type 2 diabetes, has been found to be a new drug as regulator of PD-L1 66, which provides a potential way for targeting PD-L1 immunotherapy. This evidence concerns the gene CD274 and type 2 diabetes mellitus.